Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase I/II Trial to Evaluate the Efficacy of K-NK002 (Previously CSTD002) in Decreasing Risk of Relapse in Patients with High-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Trial Profile

A Multicenter Phase I/II Trial to Evaluate the Efficacy of K-NK002 (Previously CSTD002) in Decreasing Risk of Relapse in Patients with High-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CSTD002 NK (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NK-REALM
  • Sponsors CytoSen Therapeutics; Kiadis Pharma
  • Most Recent Events

    • 06 Nov 2019 Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 According to a Kiadis Pharma media release, the company will provide an overview of this study at the 59th Annual Meeting of the American Society of Hematology (ASH, 7th Dec 2019, in Orlando, Florida).
    • 05 Jun 2019 According to a Kiadis Pharma media release, the company has finished the acquisition of CytoSen Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top